title: Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil.
authors.forename: Herwig-Ulf
authors.initials: HU
authors.lastname: Meier-Kriesche
authors.forename: Neal M
authors.initials: NM
authors.lastname: Davies
authors.forename: Josep
authors.initials: J
authors.lastname: Grinyó
authors.forename: Robert
authors.initials: R
authors.lastname: Heading
authors.forename: Richard
authors.initials: R
authors.lastname: Mamelok
authors.forename: Peter
authors.initials: P
authors.lastname: Wijngaard
authors.forename: Michael
authors.initials: M
authors.lastname: Oellerich
authors.forename: Bart
authors.initials: B
authors.lastname: Maes
mesh_terms: D002986:Clinical Trials as Topic; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D012107:Research Design
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid